Monitoring persistent GENOTYPE-SPECIFIC HPV INFECTIONS: identifying THOSE PATIENTS MOST AT RISK for developing cervical disease
Why tracking
genotype-specific HPV persistence matters
HPV infection history and current HPV results are both critical when assessing the risk for cervical cancer.1
Persistence of infections by high-risk HPV genotype is the single greatest risk factor for malignant progression.2
The BD Onclarity™ HPV Assay is the only FDA-approved assay that allows you to track persistent HPV infections using extended genotyping (detection of HPV types beyond HPV 16 and 18).3,4

Persistent genotype-specific HPV infection increase the risk of cervical disease2,5

Cumulative proportion of ≥CIN2 among women with genotype-specific HPV persistence*5





Adapted from Elfgren et al. Am J Obstet Gynecol. 2017;216:264.e1-7.
*12,527 women aged 32-38 years with follow up of 195 women attending colposcopy who were cytologically normal but persistently HPV positive for at least 1 year.

MONITORING GENOTYPE-SPECIFIC HPV PERSISTENCE IS KEY TO IDENTIFYING YOUR PATIENTS AT MOST RISK FOR DEVELOPING CERVICAL DISEASE.1,2,5

Extended genotyping helps track genotype-specific HPV persistence

HPV infection history and current HPV results are both critical when assessing the risk for cervical cancer and guiding patient management.1



The BD Onclarity™ HPV Assay is the only FDA-approved assay that helps track genotype-specific HPV persistence using extended genotyping3,4


Learn more The value of extended genotyping
  • CIN, cervical intraepithelial neoplasia;
  • CIN2, cervical intraepithelial neoplasia grade 2;
  • FDA, Food and Drug Administration;
  • HPV, human papillomavirus;
  • hrHPV, high-risk human papillomavirus.
  1. Perkins RB et al. J Low Genit Tract Dis. 2020;24:102-131.
  2. Bodily J et al. Trends Microbiol. 2011;19(1):33-39.
  3. BD Onclarity™ HPV Assay European Product information, 8089899(14). Updated November 2020.
  4. BD Press Release. BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities. July 22, 2020.
  5. Elfgren K et al. Am J Obstet Gynecol. 2017;216(3):264.e1-7.